Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

被引：20

作者：

Zhang, Jinfeng ^{[1
,2
]}

Yan, Wenzhong ^{[1
]}

Duan, Wenwen ^{[1
]}

Wuthrich, Kurt ^{[1
,3
]}

Cheng, Jianjun ^{[1
]}

机构：

[1] ShanghaiTech Univ, IHuman Inst, Shanghai 201210, Peoples R China

[2] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China

[3] Scripps Res, Dept Integrated Struct & Computat Biol, La Jolla, CA 92037 USA

来源：

PHARMACEUTICALS | 2020年 / 13卷 / 09期

关键词：

GPCR; immuno-oncology; Parkinson's disease; drug binding modes; cancer therapy; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; DERIVATIVES; ZM241385; POTENT; ZM-241385; BLOCKADE; BINDING; CELLS;

D O I：

10.3390/ph13090237

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The A(2A) adenosine receptor (A(2A) AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A(2A) AR have been focused on the use of A(2A) AR antagonists for the treatment of Parkinson's disease. More recently, the A(2A) AR has attracted additional attention for its roles in immuno-oncology, and a number of A(2A) AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A(2A) AR antagonists for cancer immunotherapy. The therapeutic potential of representative A(2A) AR antagonists is discussed based on both animal efficacy studies and clinical data.

引用

页码：1 / 14

页数：14

共 50 条

[21] Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists
Yang, Zhaohui
Li, Xuan
Ma, Haikuo
Zheng, Jiyue
Zhen, Xuechu
Zhang, Xiaohu
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 152 - 155
[22] Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists
Shao, Yuefei
Cole, Andrew G.
Brescia, Marc-Raleigh
Qin, Lan-Ying
Duo, Jingqi
Stauffer, Tara M.
Rokosz, Laura L.
McGuinness, Brian F.
Henderson, Ian
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (05) : 1399 - 1402
[23] Pharmacophore modeling of human adenosine receptor A2A antagonists
Zhejun Xu
Feixiong Cheng
Chenxiao Da
Guixia Liu
Yun Tang
Journal of Molecular Modeling, 2010, 16 : 1867 - 1876
[24] Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists
Szabo, Nikoletta
Kincses, Zsigmond Tamas
Vecsei, Laszlo
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (04) : 441 - 455
[25] Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?
Jost, Wolfgang H.
Toenges, Lars
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2022, 90 (12) : 565 - 570
[26] Adenosine A2A Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Khanapur, S.
van Waarde, A.
Ishiwata, K.
Leenders, K. L.
Dierckx, R. A. J. O.
Elsinga, P. H.
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (03) : 312 - 328
[27] Involvement of globus pallidus in the antiparkinsonian effects of adenosine A2A receptor antagonists
Simola, Nicola
Fenu, Sandro
Baraldi, Pier G.
Tabrizi, Moigan Aghazadeh
Morelli, Micaela
EXPERIMENTAL NEUROLOGY, 2006, 202 (01) : 255 - 257
[28] Striatal Pre- and Postsynaptic Profile of Adenosine A2A Receptor Antagonists
Orru, Marco
Bakesova, Jana
Brugarolas, Marc
Quiroz, Cesar
Beaumont, Vahri
Goldberg, Steven R.
Lluis, Carme
Cortes, Antoni
Franco, Rafael
Casado, Vicent
Canela, Enric I.
Ferre, Sergi
PLOS ONE, 2011, 6 (01):
[29] History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents
Preti, Delia
Baraldi, Pier Giovanni
Moorman, Allan R.
Borea, Pier Andrea
Varani, Katia
MEDICINAL RESEARCH REVIEWS, 2015, 35 (04) : 790 - 848
[30] Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
Xu, K
Bastia, E
Schwarzschild, M
PHARMACOLOGY & THERAPEUTICS, 2005, 105 (03) : 267 - 310

← 1 2 3 4 5 →